Inhibitors of factor VIIa/tissue factor

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 27, Issue 9, 2007, Pages 1895-1900

  Shirk, Rebecca A ^a   Vlasuk, George P ^a  

^a PFIZER INC   (United States)

Author keywords

Anticoagulants; Coagulation; Factor VIIa (FVIIa); Serine protease inhibitors; Tissue factor

Indexed keywords

5 AMIDINOINDOLE; AMIDINE; AMIDOXIME; ANTICOAGULANT AGENT; APIXABAN; ARGININE; BENZAMIDINE; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A INHIBITOR; BMS 562247; CARBAMIC ACID; CRA 027483; DABIGATRAN ETEXILATE; FIBRINOGEN RECEPTOR ANTAGONIST; LY 517717; MELAGATRAN; PHA 927; PHYTOHEMAGGLUTININ; PRODRUG; RAZAXABAN; RIVAROXABAN; THROMBOPLASTIN; UNCLASSIFIED DRUG; XIMELAGATRAN;

ARTERY INJURY; BLEEDING; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG MEGADOSE; ENDOTOXEMIA; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; THROMBOSIS;

ANTICOAGULANTS; DRUG DESIGN; FACTOR VIIA; HUMANS; SERINE PROTEINASE INHIBITORS; THROMBOPLASTIN;

EID: 34548163390     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.148304     Document Type: Short Survey

References (46)

1. Steffel J, Lüscher TF, Tanner FC. Tissue factor in cardiovascular disease. Molecular mechanisms and clinical implications. Circulation. 2006; 113:722-731.
2. De Caterina R, Husted S, Wallentin L, Agnelli G, Bachman F, Baigent C, Jespersen J, Kristensen SD, Montalescot G, Siebahn A, Verheugt FWA, Weitz J. Anticoagulants in heart disease: current status and perspectives. Eur Heart J. 2007;28:880-913.
3. Harker LA, Hanson SR, Wilcox JN, Kelly AB. Antithrombotic and antilesion benefits without hemorrhagic risk by inhibiting tissue factor pathway. Haemostasis. 1996;26(Suppl 1):76-82.
4. Himber J, Kirchhofer D, Riederer M, Tschopp TB, Steiner B, Roux SP. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function. Thromb Haemost. 1997;78:1142-1149.
5. Golino P, Ragni M, Cirillo P, D'Andrea D, Scognamiglio A, Ravera A, Buono C, Ezban M, Corcione N, Vigorito F, Condorelli M, Chiariello M. Antithrombotic effects of recombinant human, active site-blocked factor VIIa in a rabbit model of recurrent arterial thrombosis. Circ Res. 1998;82:39-46.
6. Himber J, Whohlgensinger C, Rouz S, Damico LA, Fallon JT, Kirchhofer D, Nemerson Y, Rieder MA. Inhibition of tissue factor limits the growth of venous thrombosis in the rabbit. J Thromb Haemost. 2003;1:889-895.
7. Suleymanov OD, Szalony JA, Salyers AK, LaChance RM, Parlow JJ, South MS, Wood RS, Nicholson NS. Pharmacological interruption of acute thrombosis formation with minimal hemorrhagic complications by a small molecule tissue factor/factor VIIa inhibitor: Comparision to factor Xa and thrombin inhibition in a nonhuman primate thrombosis model. J Pharmacol Exp Ther. 2003;306:1115-1121.
8. Olivero AG, Eigenbrot G, Goldsmith R, Robarge K, Artis DR, Flygare J, Rawson T, Sutherlin DP, Kadkhodayan S, Beresini M, Elliott LO, DeGuzman GG, Banner DW, Ultsch M, Marzec U, Hanson SR, Refino C, Bunting S, Kirchhofer D. A selective, slow binding inhibitor of factor VIIa binds to a nonstandard active site conformation and attenuates thrombus formation in vivo. J Biol Chem. 2005;280:9160-9169.
9. Lazarus RA, Olivero AG, Eigenbrot C, Kirchhofer D. Inhibitors of tissue factor-factor VIIa for anticoagulant therapy. Curr Med Chem. 2004;11:2275-2290.
10. Frédérick R, Pochet L, Charlier C, Masereel B. Modulators of the coagulation cascade: focus and recent advances in inhibitors of tissue factor, factor VIIa and their complex. Curr Med Chem. 2005;12:397-417.
11. Kranjc A, Kikelj D, Peterlin-Masic L. Recent advances in the discovery of tissue factor/factor VIIa inhibitors and dual inhibitors of factor VIIa/factor Xa. Curr Pharm Design. 2005;11:4207-4227.
12. Lee AYY, Vlasuk GP. Recombinant nematode anticoagulant protein c2 and other inhibitors targeting blood coagulation factor VIIa/tissue factor. J Internal Med. 2003;254:313-321.
13. Banner DW, D'Arcy A, Chène C, Winkler FK, Guha A, Konigsberg WH, Nemerson Y, Kirchhofer D. The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature. 1996;380:41-46.
14. Schweitzer BA, Neumann WL, Rahman HK, Kusturin CL, Sample KR, Poda GI, Kurumbail RG, Stevens AM, Stegeman RA, Stallings WC, South MS. Structure-based design and synthesis of pyrazinones containing novel P1 'side pocket' moieties as inhibitors of TF/VIIa. Bioorg Med Chem Lett. 2005;15:3006-3011.
15. Kohrt JT, Filipski KJ, Cody WL, Cai C, Dudley DA, Van Huis CA, Willardsen JA, Rapundalo ST, Saiya-Cork K, Leadley RJ, Narasimhan L, Zhang E, Whitlow M, Adler M, McLean K, Chou Y-L, McKnight C, Arnaiz DO, Shaw KJ, Light DR, Edmunds JJ. The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex. Bioorg Med Chem Lett. 2005;15:4752-4756.
16. Zbinden KG, Banner DW, Ackermann J, D'Arcy A, Kirchhofer D, Ji Y-H, Tschopp TB, Wallbaum S, Weber L. Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005;15:817-822.
17. Shrader WD, Kolesnikov A, Burgess-Henry J, Rai R, Hendrix J, Hu H, Torkelson S, Ton T, Young WB, Katz BA, Yu C, Tang J, Cabuslay R, Sanford E, Janc JW, Sprengeler PA. Factor VIIa inhibitors: gaining selectivity within the trypsin family. Bioorg Med Chem Lettr. 2006;16:1596-1600.
18. Young WB, Mordenti J, Torkelson S, Shrader WD, Kolesnikov A, Rai R, Liu L, Hu H, Leahy EM, Green MJ, Sprengeler PA, Katz BA, Yu C, Janc JW, Elrod KC, Marzec UM, Hanson SR. FVIIa inhibitors: chemical optimization, preclinical pharmacokinetics, pharmacodynamics, and efficacy in an arterial baboon thrombosis model. Bioorg Med Chem Lett. 2006;16:2037-2041.
19. Zbinden KG, Obst-Sander U, Hilpert K, Kühne H, Banner DW, Böhm H-J, Stahl M, Ackermann J, Alig L, Weber L, Wessel HP, Riederer MA, Tschopp TB, Lavé T. Selective and orally bioavailable phenylglycine tissue factor/factor VIIa inhibitors. Bioorg Med Chem Lett. 2005;15:5344-5352.
20. Zbinden KG, Banner DW, Hilpert K, Himber J, Lavé T, Riederer MA, Stahl M, Tschopp TB, Obst-Sander U. Dose-dependent antithrombotic activity of an orally active tissue factor/factor VIIa inhibitor without concomitant enhancement of bleeding propensity. Bioorg Med Chem. 2006;14:5357-5369.
21. Kolesnikov A, Rai R, Young WB, Mordenti J, Liu L, Torkelson S, Shrader WD, Leahy EM, Hu H, Gjerstad E, Janc J, Katz BA, Sprengeler PA. Factor FVIIa inhibitors: Improved pharmacokinetic parameters. Bioorg Med Chem Lett. 2006;16:2243-2246.
22. Kadona S, Sakamoto A, Kikuchi Y, Oh-eda M, Yabuta N, Koga T, Hattori K, Shiraishi T, Haramura M, Kodama H, Ono Y, Esaki T, Sato H, Watanabe Y, Itoh S, Ohta M, Kozono T. Structure of human factor VIIa/tissue factor in complex with a peptide-mimetic inhibitor: high selectivity against thrombin by introducing two charged groups in P2 and P4. Acta Cryst. 2005;F61:169-173.
23. Kohrt JT, Filipski KJ, Cody WL, Cai C. Dudley DA, Van Huis CA, Willardsen JA, Narasimhan LS, Zhang E, Rapundalo ST, Saiya-Cork K, Leadley RJ, Edmunds JL. The discovery of fluoropyridine-based inhibitors of the factor VIIa/TF complex - Part 2. Bioorg Med Chem Lett. 2006;16:1060-1064.
24. Riggs JR, Hu H, Kolesnikov A, Leahy EM, Wesson KE, Shrader WD, Vijaykumar D, Wahl TA, Tong Z, Sprengeler PA, Green MJ, Yu C, Katz BA, Sanford E, Nguyen M, Cabuslay R, Young WB. Novel 5-azaindole factor VIIa inhibitors. Bioorg Med Chem Lett. 2006;16:3197-3200.
25. Himber J, Burcklen L, Tschopp T, Fingerle J, Bunting S, Steiner B, Riederer MA. Efficacy and safety of selective inhibitors of thrombin, FXa, and FVIIa in a guinea pig arterial thrombosis model. Thromb Haemost. 2001;Supplement:abstract #P1387.
26. Fingerle J, Himber J, Tschopp T, Bunting S, Steiner B, Riederer MA. Minimal bleeding risk after chronic application of factor VIIa inhibitor in a guinea pig model. Thromb Haemost. 2001;Supplement:abstract #OC1766.
27. Szalony JA, Suleymanov OD, Salyers AK, Panzer-Knodle SG, Blom JD, LaChance RM, Case BL, Parlow JJ, South MS, Wood RS, Nicholson NS. Administration of a small molecule tissue factor/factor VIIa inhibitor in a non-human primate thrombosis model of venous thrombosis: effects on thrombus formation and bleeding time. Thromb Res. 2003;112:167-174.
28. Arnold CS, Parker C, Upshaw R, Prydz H, Chand P, Kotian P, Bantia S, Babu YS. The antithrombotic and anti-inflammatory effects of BCX-3607, a small molecule tissue factor/factor VIIa inhibitor. Thromb Res. 2006;117:343-349.
29. Wong P, Crain E, Watson C, Staus A, Luettgen J, Rendina A, Abell L, Knabb R, Baomin X, Zhou J, DeLucca I, Priestley E. Evaluation of a novel direct factor VIIa inhibitor in rabbit models of arterial thrombosis and hemostatis. J Thromb Haemost. 2005;3(supplement 1):abstract #P0162.
30. Marzec UM, Sukbuntherng J, Dalrymple SA, Young WB, Vijaykumar D, Young PR, Hanson SR. Subcutaneous dosing of CRA-027483, a small molecule FVIIa inhibitor, prevents arterial thrombosis in a baboon model. Blood. 2005;106:abstract#1867.
31. Dalrymple SA, San Pablo FD, Sukbentherng J, Janc JW, Young WB, Vijaykumar D. A selective small molecule factor VIIa inhibitor, CRA-027483, suppressed acute inflammation in mice. Blood. 2005;106:abstract#3089.
32. Hu H, Kolesnikov A, Riggs JR, Wesson KE, Stephens R, Leahy EM, Shrader WD, Sprengeler PA, Green MJ, Sanford E, Nguyen M, Gjerstad E, Cabuslay R, Young WB. Potent 4-amino-5-azaindole factor VIIa inhibitors. Bioorg Med Chem Lett. 2006;16:4567-4570.
33. Rai R, Kolesnikov A, Sprengeler PA, Torkelson S, Ton T, Katz BA, Yu C, Hendrix J, Shrader WD, Stephens R, Cabuslay R, Sanford E, Young WB. Discovery of novel heterocyclic factor VIIa inhibitors. Bioorg Med Chem Lett. 2006;16:2270-2273.
34. Miura M, Seki N, Koike T, Ishihara T, Niimi T, Hirayama F, Shigenaga T, Sakai-Moritani Y, Kawasaki T, Sakamoto S, Okada M, Ohta M, Tsukamato S. Potent and selective TF/FVIIa inhibitors containing a neutral P1 ligand. Bioorg Med Chem. 2006;14:7688-7705.
35. Miura M, Seki N, Koike T, Ishihara T, Niimi T, Hirayama F, Shigenaga T, Sakai-Moritani Y, Tagawa A, Kawasaki T, Sakamoto S, Okada M, Ohta M, Tsukamato S. Design, synthesis and biological activity of selective and orally available TF/FVIIa complex inhibitors containing non-amidine P1 ligands. Bioorg Med Chem. 2007;15:160-173.
36. Peterlin-Masic L, Cesar J, Zega A. Metabolism-directed optimization of antithrombotics: the prodrug principle. Curr Pharm Des. 2006;12:73-91.
37. Riggs JR, Kolesnikov A, Hendrix J, Young WB, Shrader WD, Vijaykumar D, Stephens R, Liu L, Pan L, Mordenti J, Green MJ, Sukbenterng J. FVIIa inhibitors: A prodrug strategy to improve oral bioavailability. Bioorg Med Chem Lettr. 2006;16:2224-2228.
38. Preželj A, Štefanič P, Peternel L, Urleb U. Recent advances in serine protease inhibitors as anticoagulant agents. Curr Pharm Design. 2007; 13:287-312.
39. Turpie AGG. Oral direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2007;27:1238-1247.
40. Gustafsson D, Elg M. The pharmacodynamics and pharmacokinetics of the oral direct thrombin inhibitor ximelagatran and its active metabolite melagatran: a mini-review. Thromb Res. 2003;109:S9-S15.
41. Hampton T. New oral anticoagulants show promise. J Am Med Assoc. 2006;295:743-744.
42. Roehrig S, Straub A, Pohlmann J, Lampe T, Pernerstorfer J, Schlemmer K-H, Reinemer P, Perzborn E. Discovery of the novel antithrombotic agent 5-chloro-N-({(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1, 3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide (BAY-59-7939): an oral, direct FXa inhibitor. J Med Chem. 2005;48:5900-5908.
43. Quan ML, Lam PYS, Han Q, Pinto DJP, He MY, Li R, Ellis CD, Clark CG, Teleha CA, Sun J-H, Alexander RS, Bai S, Luettgen JM, Knabb RM, Wong PC, Wexler RR. Discovery of 1-(3′-Aminobenzisoxazol-5′-yl)-3-trifluoromethyl- N-[2-fluoro-4-[(2′-dimethylaminomethyl)imidazol-1-yl]phenyl] -1H-pyrazole-5-carboxyamide hydrochloride (Razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem. 2005;48:1729-1744.
44. Adler M, Kochanny MJ, Ye B, Rumennik G, Light DR, Biancalana S, Whitlow M. Crystal structures of two potent nonamidine inhibitors bound to factor Xa. Biochemistry. 2002;41:15512-15523.
45. Choi-Sledeski YM, Kearney R, Poli G, Pauls H, Gardner C, Gong Y, Becker M, Davis R, Spada A, Liang G, Chu V, Brown D, Collussi D, Leadley R, Rebello S, Moxey P, Morgan S, Bentley R, Kasiewski C, Maignan S, Guilloteau J-P, Mikol V. Discovery of an orally efficacious inhibitor of coagulation factor Xa which incorporates a neutral P1 ligand. J Med Chem. 2003;46:681-684.
46. Pruitt JR, Pinto DJP, Galemmo RA, Alexander RS, Rossi KA, Wells BL, Drummond S, Bostrom LL, Burdick D, Bruckner R, Chen H, Smallwood A, Wong PC, Wright MR, Bai S, Luettgen JM, Knabb RM, Lam PYS, Wexler RR. Discovery of 1-(2-Aminomethylphenyl)-3-trifluoromethyl-N-[3-fluoro-2′- (aminosulfonyl)[1,1′-biphenyl)]-4-yl]-1H-pyrazole-5-carboxyamide (DPC602), a potent, selective, and orally bioavailable factor Xa inhibitor. J Med Chem. 2003;46-5298-5315.